DTIL

Analyst Note: Precision BioSciences, Inc. (DTIL)

Date: 2026-06-12 Current Price: $6.81

1. Structural Readiness

• State: FORMING
• Aggressive/Pre-Breakout Entry: N/A (Current price is within the consolidation range; entry is typically reserved for the breakout confirmation or a retest of the formed support).
• Breakout Level: $7.45 (Resistance zone identified from the May 2026 high).
• Current Price: $6.81.
• Extension: N/A (Price is within the consolidation range, not extended above the breakout level).
• ATR Context: Current ATR is 8.6% (Extreme). This indicates high volatility and significant risk of whipsaw during the formation phase. The ATR at breakout is not yet established as the breakout has not occurred.

2. Thesis Layer

• Primary Secular Thesis: biotech_platform_breakthroughs
• Role & Directness: Precision BioSciences is a direct beneficiary and primary driver of this thesis. The company is executing a "global first-in-human" clinical trial for PBGENE-HBV, targeting the elimination of cccDNA, which represents a potential curative mechanism for chronic Hepatitis B. This aligns directly with the secular shift toward curative gene editing rather than chronic management.
• Additional Secular Tailwinds:
• Allogeneic CAR-T Expansion: The company is advancing ex vivo allogeneic CAR T therapies (PBCAR19B, PBCAR269A) and has secured partnerships (Servier, Tiziana Life Sciences) to expand the addressable market beyond autologous limitations.
• Rare Disease Acceleration: The Fast-Track and Orphan Drug designations for PBGENE-DMD provide regulatory tailwinds specific to the rare disease sector.

3. The Business

Precision BioSciences, Inc. is a clinical-stage biotechnology firm specializing in in vivo gene editing (ARCUS platform) and ex vivo allogeneic CAR T-cell therapies.

• Core Platform: The ARCUS platform utilizes complementary nucleases delivered in a single AAV to excise specific gene sequences.
• *Evidence:* As of May 2026, the company has treated 16 patients with 38 administrations of PBGENE-HBV across five cohorts (E1). The program targets cccDNA, the sole source of HBV viral replication (E5).
• *Evidence:* The PBGENE-DMD program is designed to improve function in ~60% of DMD patients by excising exons 45-55 (E6, E15).
• Clinical Progress:
• *HBV:* The Phase 1/2a ELIMINATE-B trial is active. In April 2026, the company activated Arkansas Children's Hospital as a new site and expanded the study to France and Romania (E3, E4). Management expects to share further clinical data at EASL and other conferences throughout 2026 (E2).
• *DMD:* The FUNCTION-DMD study is enrolling ambulatory patients. Initial data from multiple patients is expected by year-end 2026 (E10, E11).
• *CAR-T:* PBCAR0191 is in Phase 1/2a for R/R NHL/B-ALL. PBCAR269A targets BCMA for multiple myeloma (E24, E25).
• Financial Position & Capital:
• *Evidence:* In early 2026, the company secured a $7.5 million cash payment from TG Therapeutics, including $5.25 million cash and $2.25 million in stock (E7).
• *Runway:* Management states that as of the March 2026 10-Q, existing cash, operating discipline, and the ATM facility are sufficient to fund operations through 2028 (E8).
• Partnerships:
• Collaboration with iECURE for ARCUS-based therapies (E18).
• Agreement with Servier for allogeneic CAR T development (E22).
• Collaboration with Tiziana Life Sciences for lymphodepleting agents (E17).

4. Archetype and Conviction

• Archetype: Growth Leader / Clinical Catalyst
• *Fit:* The company is not a deep value recovery or a cyclical operator. It is a high-conviction growth story driven by binary clinical milestones (data readouts) and platform expansion. The "Growth Leader" archetype fits because the company is defining the standard for in vivo cccDNA elimination and expanding its allogeneic footprint.
• Valuation Context: The company is pre-revenue for its core programs, relying on cash reserves and equity financing. The $7.5M raise and 2028 runway provide a buffer, but the valuation is entirely dependent on the successful execution of the 2026 data readouts.
• Conviction Stack:
• *Thesis Strength:* High. The cccDNA target is a significant unmet need with a clear mechanism of action.
• *Evidence Quality:* Strong. Multiple primary filings (E1-E12) confirm active enrollment, site expansion, and regulatory designations (Fast-Track, Orphan).
• *Rerating Potential:* High, contingent on the May/June 2026 data readouts and the subsequent EASL presentation.

5. Invalidation, Strengthening, and Gaps

• What Would Invalidate:
• Negative safety signals or lack of efficacy in the upcoming PBGENE-HBV or PBGENE-DMD data readouts expected in late 2026.
• A breach of the 2028 cash runway due to unexpected operational costs or inability to access the ATM facility.
• What Would Strengthen:
• A confirmed breakout above $7.45 with volume, signaling institutional accumulation ahead of the EASL data.
• Positive interim data from the Arkansas Children's Hospital site or the European expansion sites.
• Additional partnership announcements or licensing deals (similar to the TG Therapeutics deal).
• Gaps in Evidence:
• Specific Efficacy Metrics: While the *expectation* of data is clear (E2, E11), the specific quantitative efficacy numbers (e.g., % of patients achieving HBsAg loss) are not yet available as of June 12, 2026. The market is currently pricing in *hope* of data, not the data itself.
• Commercialization Path: There is no evidence regarding pricing strategy or reimbursement pathways for the curative HBV therapy, which is a critical gap for long-term valuation.
• Manufacturing Scale: No specific evidence on the scalability of the ARCUS platform for commercial manufacturing volumes is provided in the current filings.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: 1) PBGENE-HBV is the only clinical stage program targeting cccDNA elimination with 16 patients treated across 5 cohorts. 2) Management has secured a 2028 cash runway via recent capital raise and ATM facility. 3) Regulatory tailwinds including Fast-Track and Orphan Drug designations for PBGENE-DMD. Key risks: 1) Extreme volatility (8.6% ATR) creates high risk of stop-outs during the forming coil phase. 2) Binary clinical risk: failure to demonstrate efficacy in late 2026 data readouts. 3) Lack of near-term revenue; reliance on equity financing. Sizing hint: Position size should be reduced relative to a confirmed breakout due to the "Extreme" ATR and pre-data status. Expected path: Price likely consolidates near current levels ($6.50-$7.50) as the market awaits the EASL presentation and late-year DMD data. A breakout above $7.45 would signal institutional accumulation. Expected horizon: 6 to 12 months (aligned with the EASL conference and year-end DMD data expectations).